Press Release May 13 2026
Filed with NSE · · 6 pages · English
(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Press Release Sub: Press Release Rajendra Chopra Company Secretary Encl: As above Prepared by: Neelam Padwad Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corpor
In the deck
Earlier from Cipla
- Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA
- Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis
- Cipla strengthens US portfolio with the launch of generic Saxenda(R) (Liraglutide Injection) for weight management therapy
- Cipla strengthens US portfolio with the launch of generic Saxenda for weight management therapy
- Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
Later from Cipla
- Cipla Ltd Press Release Jul 23 2026
- Cipla Ltd Press Release Aug 31 2026
- Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
- Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda in the US
- Cipla Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Q2FY27 Financial Results".
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla